Modern opportunities of heart rate regulation in coronary heart disease
| Autor: | Zagidullin, N. S., Gareeva, D. F., Zagidullin, B. I., Travnikova, E. O., Zulkarneev, R. K., Zagidullin, S. Z. |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Framingham Risk Score business.industry Sinoatrial node heart failure ivabradine medicine.disease Clinical trial medicine.anatomical_structure Internal medicine Heart failure RC666-701 Heart rate medicine Cardiology heart rate Diseases of the circulatory (Cardiovascular) system Myocardial infarction Risk factor coronary heart disease Cardiology and Cardiovascular Medicine business Ivabradine medicine.drug |
| Zdroj: | Российский кардиологический журнал, Vol 0, Iss 5, Pp 61-65 (2013) Scopus-Elsevier |
| ISSN: | 2618-7620 1560-4071 |
| Popis: | It has been demonstrated that high heart rate (HR) levels are an independent risk factor of cardiovascular events and mortality from coronary heart disease and chronic heart failure (CHF). Recently, the so-called If-inhibitors which selectively block the pacemaker current in sinoatrial node cells (ivabradine, or Coraxan®) have been introduced to clinical practice. The latest large randomised clinical trials, such as SHIFT and BEAUTIFUL, have shown that in patients with stable effort angina, CHF, and HR >70 bpm, ivabradine reduces the incidence of cardiovascular end-points: myocardial infarction, coronary interventions, hospitalisations, and other events. These results justified the inclusion of ivabradine in the international clinical guidelines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|